Test Before Treat™ One-pager
In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.
The PDF document below is a one-page summary of what you need to know about the three most important tests that need to be performed to guide your CLL or SLL treatment selection.
Please read it and print it out to share with your healthcare provider, if need be, or with other patients who might also benefit from this information.
ADDITIONAL READING
At the time of my initial diagnosis — and not because I knew any better, because I knew nothing at all including my not-yet-announced diagnosis – my hematologist ran both a flow cytometry (to diagnose my disease) and a FISH analysis (to explore the genetics of my CLL). Though
Doctors on The Importance of Test Before Treat™ in Treating CLL: We have been saying TEST BEFORE TREAT™ was critical, but you don’t have to just take our word for it. The iwCLL and NCCN guidelines have confirmed our mantra. So do leading CLL doctors, including: Dr. Anthony Mato
I was diagnosed July of 2018 by a local oncologist, CLL stage 4. He wanted to treat me immediately with BR. I asked him about trials because I did not want to do chemo and read about some superior non- chemo meds. He said he would check, and afterwards, said there
I was diagnosed February 6, 2018. I began immediate treatment for B-symptoms (have had them since 2008) – completed 6 of ten rounds Rituxan (had to stop due to Rituxan-induced colitis). My oncologist failed to determine mutated/unmutated status – she was fired. I now see a CLL Specialist. Relapsed
In this last of four interviews from Barcelona, 2018 with Dr. Stamatopolous of ERIC, explains the importance of testing of IgHV. Takeaways: Unlike other prognostic and predictive factors, doesn’t change over time. iwCLL guidelines state the IgHV testing must be done before the first treatment. This isn’t just interesting
By Brian Koffman, MD There are many prognostic and predictive tests that can be ordered at different times on our CLL journey. Let’s start by saying that there is no consensus on this issue and different doctors have different opinions. I am sharing mine. Here are my own thoughts
We have to know our enemy before we decide how to best target therapy. That is why performing certain biomarker testing before considering any type of CLL treatment is critical, and why it is tragic when it is not being done. At ASH 2018, I interviewed Dr. Anthony Mato,
In a conversation at the December 2018 ASH meeting with Dr. Brian Koffman, Chief Medical Officer and EVP of the CLL Society, he and Dr. Kamala Maddali reviewed the latest research and her experience about what she calls the “cultural shift” in how chronic lymphocytic leukemia is diagnosed and
